FBPixel Alzheimer’s Reversal is Real - Interview with Dr. Dale Bredesen

Alzheimer’s Reversal is Real

Most everyone knows of a cancer survivor. But, by and large, when a person receives a diagnosis of Alzheimer’s disease, it is often assumed that this is an indication of an almost certain outcome.

Alzheimer’s disease is not caused by a specific flaw. While energy deficiency, inflammation, infectious agents, beta amyloid, acetylcholine deficiency, trauma, toxins, metabolic issues, and genetics are all worthy of consideration, it is clearly myopic to consider that targeting one of these popular ideas is going to solve the problem. It doesn’t.

Our guest today has taken a different approach. Rather than trying to find a unique drug or technique that can help the Alzheimer’s population at large, this novel approach focuses on identifying how variations in multiple parameters can be targeted with the overall goal of improving brain functionality that is compromised in the developing Alzheimer’s situation. This approach, a personalized medicine approach, directly challenges the notion of a one-size-fits-all mentality as it relates to treating medical problems. And to be sure, Dr. Bredesen is demonstrating incredible success not just in stabilizing Alzheimer’s patients but actually in bringing about their improvement. This is revolutionary, and I urge you to pay close attention to his message today.

Dr. Bredesen received his undergraduate degree from Caltech and his medical degree from Duke. He served as Resident and Chief Resident in Neurology at UCSF, then was postdoctoral fellow in the laboratory of Nobel laureate Prof. Stanley Prusiner. He was a faculty member at UCLA from 1989-1994, then was recruited by the Burnham Institute to direct the Program on Aging. In 1998 he became the Founding President and CEO of the Buck Institute for Research on Aging, and Adjunct Professor at UCSF; then in 2013 he returned to UCLA as the Director of the Easton Center for Alzheimer’s Disease Research.

The Bredesen Laboratory studies basic mechanisms underlying the neurodegenerative process, and the translation of this knowledge into effective therapeutics for Alzheimer’s disease and other neurodegenerative conditions, leading to the publication of over 220 research papers. He established the ADDN (Alzheimer’s Drug Development Network) with Dr. Varghese John in 2008, leading to the identification of new classes of therapeutics for Alzheimer’s disease. He and his group developed a new approach to the treatment of Alzheimer’s disease, and this approach led to the discovery of subtypes of Alzheimer’s disease, followed by the first description of reversal of symptoms in patients with MCI and Alzheimer’s disease, with the ReCODE (reversal of cognitive decline) protocol, published in 2014, 2016, and 2018. Dr. Bredesen is the author of the New York Times bestseller, The End of Alzheimer’s, and the newly released, The End of Alzheimer’s Program. His newest book, The First Survivors of Alzheimer’s, chronicles how this program has virtually rewritten the lives of so many, and reveals, from the patient’s perspective, what this has meant. Here’s a link to his latest research paper showing improvement in an astounding 80% of Alzheimer’s patients.

Enjoy today’s interview, and then watch the trailer for Dr. Bredesen’s newest book, The First Survivors of Alzheimer’s, below.

Join me on

Related Topics

The Empowering NeurologistDementiaAlzheimer’sBrain Health

Share This